Development of Radiation/Nuclear Medical Countermeasures (MCMs) And Biodosimetry Devices
ID: BAA-75N93024R00020Type: Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NIAIDBETHESDA, MD, 20892, USA

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH (AN12)

Original Source

https://sam.gov/opp/a4650159a8bf4733a63b2b7d22d5ff84/view
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) through the National Institute of Allergy and Infectious Diseases (NIAID), is soliciting proposals for the development of Radiation/Nuclear Medical Countermeasures (MCMs) and biodosimetry devices. The primary objectives are to create effective MCMs that mitigate normal tissue injuries from ionizing radiation and to advance biodosimetry tools that enhance triage and treatment strategies during radiation emergencies. This initiative is crucial for national preparedness against potential radiological incidents, as it aims to address the urgent need for medical interventions and diagnostic capabilities in mass casualty scenarios. Proposals are due by March 19, 2025, with an estimated funding of $2 million annually for successful applicants over a typical three-year contract period, totaling a possible award of $6 million. For further inquiries, interested parties may contact Albert Nguyen at nguyenal@niaid.nih.gov or Emily Bannister at emily.bannister@nih.gov.

    Point(s) of Contact
    Albert Nguyen
    nguyenal@niaid.nih.gov
    Emily Bannister
    emily.bannister@nih.gov
    Files
    Title
    Posted
    Amendment 1 - BAA-75N93024R00020.pdf
    The document is Amendment No. 1 to Solicitation No. BAA-75N93024R00020, focusing on the development of Radiation/Nuclear Medical Countermeasures (MCMs) and biodosimetry devices. It outlines funding availability and support for proposals aimed at addressing injuries from radiological events, stressing the importance of both effective treatments for radiation exposure and advanced biodosimetry tools that inform medical response strategies. Key points include a $2 million annual funding estimate for successful applicants over a typical contract period of three years, with a total possible award of $6 million. The amendment specifies that MCMs must effectively mitigate radiation injuries long after exposure, particularly for organs not covered by existing FDA-approved treatments. Additionally, it clarifies that repurposing FDA-approved drugs is encouraged and that ornation for interaction or discussions is limited to written submissions only. The overarching aim is to foster the development of innovative solutions capable of mitigating radiation effects and enhancing public health emergency preparedness in large-scale radiation incidents. Thus, the solicitation targets researchers and organizations engaged in medical countermeasures and biodosimetry, aligning with the strategic objectives of the U.S. government in protecting public health against nuclear and radiological threats.
    BAA-75N93024R00020 Development of Radiation Nuclear Medical Countermeasures (MCMs) And Biodosimetry Devices.pdf
    The solicitation outlines a Request for Proposal (RFP) from the National Institute of Allergy and Infectious Diseases (NIAID) for the development of Radiation/Nuclear Medical Countermeasures (MCMs) and biodosimetry devices. The RFP emphasizes two primary goals: creating MCMs to mitigate normal tissue injuries from ionizing radiation and advancing biodosimetry to enhance triage and treatment during radiation emergencies. Proposals must focus on one goal per submission. Submission guidelines state that proposals are due by March 19, 2025, and require registration in the System for Award Management (SAM). The estimated cost and fixed fee for the contract are to be determined (TBD). There are specific reporting requirements, including technical progress reports, which must be submitted electronically and comply with Section 508 requirements for accessibility. Key requirements include the protection of human subjects, adherence to federal regulations on financial conflicts of interest, and compliance with NIH policies promoting transparency in research. The document highlights the necessity for contractors to ensure proper handling of confidential information and human materials and mandates rigorous compliance with applicable laws. Overall, this RFP is a crucial step toward enhancing national preparedness for potential radiological emergencies.
    Presolicitation Notice BAA 75N93024R00020.pdf
    The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH under DHHS, is announcing a presolicitation for contracts focusing on the "Development of Radiation/Nuclear Medical Countermeasures (MCMs) and Biodosimetry Devices." This initiative aims to create products for assessing and treating radiation injuries from nuclear incidents, preparing them for advanced development through BARDA or the Project BioShield Act. Proposals are sought for candidate devices or MCMs aimed at diagnosing, mitigating, or treating acute radiation syndrome and delayed effects of radiation exposure, with expectations for FDA approval. Evaluation criteria include scientific rigor, technical personnel qualifications, and proposed methodologies, and are expected to span various research stages. NIAID plans to award 1-2 contracts, valued at approximately $6 million over three years, starting around March/April 2026. The submission period opens on/about December 19, 2024, and proposals must be submitted electronically via the NIAID eCPS site. This presolicitation serves the dual goals of enhancing national preparedness and advancing nuclear health technologies, reflecting the government's ongoing efforts to improve responses to public health emergencies involving radiation exposure.
    Similar Opportunities
    Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), is soliciting proposals under the Broad Agency Announcement (BAA) BAA-23-100-SOL-00004 for advanced research and development of Medical Countermeasures (MCMs) targeting chemical, biological, radiological, nuclear threats, and emerging infectious diseases, including pandemic influenza. The initiative aims to enhance public health preparedness by fostering partnerships with private organizations, government laboratories, and academic institutions to expedite the development of life-saving MCMs critical for national health security. Proposals will be evaluated based on scientific merit, technological maturity, and regulatory compliance, with an open submission period running until September 25, 2028, at 4:30 PM Eastern Time. Interested parties should direct inquiries to BARDA-BAA@hhs.gov for further information.
    Support for Evaluating and Conducting Computational and Alternative Toxicological Methods for the National Institute of Environmental Health Sciences
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institute of Environmental Health Sciences (NIEHS), is seeking proposals from small businesses to support the evaluation and conduct of computational and alternative toxicological methods. The objective of this procurement is to assist NIEHS in chemical hazard and risk assessment while minimizing the use of animal testing, focusing on areas such as population variability, developmental neurotoxicity, and carcinogenicity. This contract, which is a Cost-Plus-Fixed-Fee type, has a base period of performance from June 1, 2026, to May 31, 2027, with nine additional one-year options and a potential six-month extension. Proposals are due by December 19, 2025, and must be submitted electronically via the NIH eCPS website; interested parties can contact Jason Williams at jason.williams2@nih.gov or Lisa Schaupp at lisa.schaupp@nih.gov for further information.
    Irradiated Rodent Feed
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking proposals for the procurement of Certified and Irradiated Rodent Diet Feed NIH-07 and NTP-2000, along with Assay Analysis, under the combined synopsis/solicitation 76F40125Q132188. This opportunity is set aside for small businesses and requires adherence to specific technical standards regarding feed irradiation, contaminant analysis, nutritional content, and facility sanitation, as outlined in the solicitation documents. The goods are essential for research purposes at the National Center for Toxicological Research (NCTR) and will be procured through a Single Award Indefinite Delivery, Indefinite Quantity (ID/IQ) contract with a guaranteed minimum of $5,000 and an estimated maximum of $350,000 over a five-year ordering period. Proposals are due by December 22, 2025, at 1:00 PM Central Time, and interested parties can contact Howard Nesmith at howard.nesmith@fda.hhs.gov or by phone at 870-543-7459 for further information.
    R--RADx Award Management
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking sources for the RADx Award Management through a Special Notice. This procurement aims to identify qualified entities that can provide management consulting services related to the RADx initiative, which is crucial for enhancing COVID-19 testing capabilities and supporting public health efforts. Interested parties are encouraged to reach out to Melanie D. Suarez at melanie.suarez@nih.gov or call +1 301 827 7558 for further information regarding this opportunity. The notice emphasizes the importance of professional program management and support services in achieving the objectives of the RADx program.
    All Sites Primary Barrier Equipment and Decontamination Services
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for a firm-fixed price contract to provide All Sites Primary Barrier Equipment and Decontamination Services across various NIH locations, including the main campus in Bethesda, MD, and the NIAID Integrated Research Facility in Fort Detrick, MD. The contract aims to support the NIH's comprehensive safety program by ensuring the maintenance and decontamination of equipment used in high-level biosafety laboratories, which is crucial for maintaining a safe environment for research activities. Interested small businesses must submit their proposals by the due date of December 26, 2025, and can direct inquiries to primary contact Evguenia Mathur at jane.mathur@nih.gov or secondary contact Ashley Kinderdine at ashley.kinderdine@nih.gov for further clarification.
    DHS BROAD AGENCY ANNOUNCEMENT (BAA) RESEARCH AND DEVELOPMENT (R&D) COUNTERING WEAPONS OF MASS DESTRUCTION (CWMD)
    Homeland Security, Department Of
    Solicitation: Department of Homeland Security (DHS) is seeking Research and Development (R&D) proposals for countering Weapons of Mass Destruction (CWMD). The objective is to identify, explore, and demonstrate new technologies and capabilities to prevent, protect against, respond to, and mitigate nuclear, chemical, radiological, and biological threats and incidents. This 5-year Broad Agency Announcement (BAA) will provide an acquisition tool for innovative solutions. Proposals will be accepted within specified timeframes for various Areas of Interest (AOI) outlined in the notice. Interested parties can find more information on SAM.gov.
    Assay Development for Superior Understanding of Response and Efficacy (ASSURE)
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Office of Assistant Secretary for Preparedness and Response (ASPR BARDA), is soliciting proposals for the ASSURE program, which focuses on the development of innovative assays to evaluate immune responses to infections and vaccinations. The primary objective is to create multiplexed, high-throughput, scalable, and sample-sparing assays that can assess immune status in response to chemical, biological, radiological, and nuclear (CBRN) threats, pandemic influenza, and other emerging infectious diseases. Approximately $8 million is available for four to five awards, with proposals evaluated based on technical approach, relevant experience, and cost reasonableness. Interested parties must submit an abstract by December 18, 2025, and can contact Rebecca Harmon at rebecca.harmon@ati.org or 843.760.3358 for further information.
    NCI OA Special Notice of Subcontract Opportunity at the Frederick National Laboratory for Cancer Research
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), has issued a Special Notice regarding subcontracting opportunities at the Frederick National Laboratory for Cancer Research (FNLCR). This opportunity focuses on the need for laboratory assays and services to assess cytokines in nasal mucosa samples for up to nine phase 1 trials and two phase 2 trials related to the NextGen COVID-19 vaccine program, which is critical for advancing the National Institute of Allergy and Infectious Diseases (NIAID) mission. The FNLCR, operated by Leidos Biomedical Research, Inc., plays a vital role in cancer and AIDS research, and this notice aims to inform potential subcontractors of the requirements without constituting a formal solicitation. Interested parties can reach out to Tara Phillips at tara.phillips@nih.gov for further details regarding Solicitation/RFP No. S26-111, with a response date set for January 14, 2026.
    PREVENT Cancer Preclinical Drug Development Program
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to increase the programmatic ceiling for several contracts under the PREVENT Cancer Preclinical Drug Development Program. This initiative aims to enhance funding for ongoing contracts numbered 75N91019D00012 through 75N91019D00026, which are focused on health research and development services critical to advancing cancer treatment options. The adjustments to the contract values are essential for supporting continued research efforts in the field of cancer prevention and treatment. For further inquiries, interested parties can contact Rachel Turk at rachel.turk@nih.gov.
    BROAD AGENCY ANNOUNCEMENT (BAA) RESEARCH AND DEVELOPMENT IN SUPPORT OF THE JOINT PROGRAM EXECUTIVE OFFICE FOR CHEMICAL, BIOLOGICAL, RADIOLOGICAL AND NUCLEAR DEFENSE (JPEO-CBRND), JPM MEDICAL AND JPL EB
    Dept Of Defense
    Solicitation DEPT OF DEFENSE is seeking research and development services in support of the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB. The service being procured is for the identification of the best available science in the areas of research interest, including novel solutions and improved methods for developing medical countermeasures. The government is specifically interested in enabling technologies, life cycle bioinformatics, and improved logistics tracking. The procurement notice is available on SAM.gov and the JPEO-CBD website. Potential offerors are encouraged to communicate with the JPMO technical contacts for proposal ideas. For any questions or inquiries, contact usarmy.detrick.mcs.mbx.baa@mail.mil.